BioHarvest Sciences’ Post

🌟CalCog Quarterly Update🌟 The Caligor Coghlan team is excited to share our first digital newsletter. 👇 Follow the link below to explore this issue. #calcog #biotechtrends #clinicaltrials #clinicalsupply

Curious about what we do at SK pharmteco? Interested in our latest endeavors with peptides and oligos? Check out the full interview with Rizwan Chaudhrey at #BIO2024 below! #Peptides #Oligos #BIO2024 #analyticalservices

Shout out to all my buddies in Philly! Exciting things are happening for CRB in Philadelphia! Juan Tobon shares his career journey and outlines a strategic move that will allow CRBers to better serve our local clients. Read his feature on BioBuzz at the link below. #LifeSciences #PhillyBiotech #biotech

Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023   We are pleased to announce that we, as the Biotest Group, recorded sales revenues of €500.3 million in the first nine months of the current fiscal year, an increase of 38.7 % compared to sales in the same period last year.   Earnings before interest and taxes (EBIT) in the first nine months of fiscal year 2023 increased to €125.4 million (same period last year: € -19.0 million).   The revenue growth in sales and the EBIT development are mainly due to the sales and earnings effect from technology disclosure and development services with Grifols as part of the technology transfer and licensing agreement.   The detailed Q3 report can be found here: https://lnkd.in/e7QEsE3D (Clicking on the link will redirect you to an external page).   #Biotest #FromNatureForLife #Healthcare #QuarterlyReport #Q3Figures #Report

Biotest increases sales in the first half of 2024 by 35% to 372 million €   We are pleased to announce that we, as the Biotest Group, recorded sales revenues of € 372.0 million in the first half of the current fiscal year, an increase of 35.1% compared to sales in the same period last year.   Compared to the prior-year period, consolidated EBIT grew to € 78.4 million in the first six months of the 2024 financial year (prior-year period: € 19.8 million). This growth mainly reflected the earnings effect from technology disclosure and development services as part of the technology and licence agreement with Grifols.   The full Half Year Report 2024 will be published on our website on the 6th of August.   #Biotest #FromNatureForLife #Healthcare #Halfyearsfigures 

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to reveal the company's Q3 2023 results, which demonstrate remarkable growth for its flagship product, Vinia. The company achieved its projected $3.24 million in revenue for the quarter, representing a 113% increase compared to the same quarter last year and an 18% increase compared to Q2 2023. Sobel also highlighted the significant improvement in the company's gross profit margin, which reached 45% in Q3 2023 compared to 18% in Q3 2022 and 40% in Q2 2023. This margin is expected to continue to rise as production scales up. In addition, BioHarvest Sciences has seen substantial growth in its total active network of subscribers, which has increased by 213% compared to Q3 2022. Watch at #Proactive #ProactiveInvestors #CSE #OTC #BHSC #CNVCF http://ow.ly/zFoI1054Fek

Check out the latest UK Price Watch article in the Generics Bulletin for analysis and insight on February’s product launches, the biggest risers, the biggest fallers and the fastest movers…. with market data provided by WaveData. Dave Wallace, editor at Generics Bulletin, comments 'Multiple UK Generics see triple digit rises in February...... A raft of different generics saw their average UK trade price more than double....' Full article: https://lnkd.in/eKEsjEH6 More about WaveData: www.wavedata.co.uk #pharmaindustry #pharmapricing #genericmedicines

Check out the latest UK Price Watch article in the Generics Bulletin for analysis and insight on May’s product launches, the biggest risers, the biggest fallers and the fastest movers…. with market data provided by WaveData.   Dave Wallace, editor at Generics Bulletin, comments ‘Pregabalin topped our table of Biggest Risers in May, in another month of multiple treble-digit-percentage average price increases for the UK generics market.’ Full article: https://lnkd.in/e8ZdmS8U   More about WaveData: www.wavedata.co.uk #pharmaindustry #pharmapricing #genericmedicines

Are you attending the BIO International Conference? Stop by booth 3647 to learn how Kneat Gx can save you time and resources by digitizing all validation processes. #BIOInternationalConference #KneatGx #ValidationProcesses

📢 Scorpius Holdings' Massive Expansion in San Antonio: Biomanufacturing Services Soar! 📢 Scorpius Holdings has expanded its San Antonio site with a new storage and testing facility. The upgrade increases the company's warehouse space from 3,000 to 22,000 square feet, in response to growing demand for its biomanufacturing services. The facility will feature specialized storage areas with controlled temperatures and accommodate bulk drug substance storage. It will also offer in-house stability storage capabilities, providing additional revenue opportunities for Scorpius. #BioprocessUpdates #ScorpiusHoldings #SanAntonioExpansion #StorageFacility #TestingFacility #Biomanufacturing #WarehouseUpgrade #ControlledTemperatureStorage #BulkDrugSubstanceStorage #StabilityStorage #InHouseStorage #RevenueOpportunities #GrowingDemand #FacilityExpansion #StorageExpansion #BiotechServices ▷ Read the full article here: 📎 https://lnkd.in/eG2nmJVZ